GB2104527A - Antigens as immunostimulant adjuvants - Google Patents

Abstract

The problem associated with conventional methods of raising antibodies is that low antibody titres result, which can be overcome by an antigen comprising killed bacteria selected from the strains Listeria monocyteogenes NRRL B-11,233, Bordetella pertussis NRRL B-11,232, Corynebacterium parvum NRRL B-11,234 and Corynebacteriam paragranulosum NRRL B-11,235, a protein extract obtained from a culture medium in which one of said strains has grown, or a plant extract of the plant species Rhus. This antigen can be incorporated in an antigen conjugate as an immunostimulant adjuvant which is coupled to a secondary antigen. When injected into a patient the conjugate results in the production of antibody specific to the secondary antigen. Consequently, the conjugate can be used to treat, for example, tumors by ensuring the secondary antigen in the conjugate is a tumor cell which is the same type of tumor as that from which the intended patient is suffering.

Description

SPECIFICATION Antigens as immunostimulant adjuvants This invention relates to certain antigens, to the production of antibodies specific thereto, to antigen conjugates and to their method of manufacture, and to injectable formulations containing the antigens, antibodies and antigen conjugates.

Immunity is an everyday word applied to a special category of defenses possessed by the body by means of which infectious agents may be checked or destroyed even after they have entered the body tissues. When a person or animal becomes immune to a disease, the immunity is largely due to the development within the body of substances capable of destroying or inactivating the causative agent of the disease, should it gain access to the body at a later time. These substances, known as antibodies or immune bodies, are produced by the body in response to a specific stimulus. Microbes and their products within the body may stimulate the body cel Is to antibody production. Other substances that may accomplish the same effect include red blood cells and serum from other animals, and other proteins.These substances are collectively known as antigens and are generally of high molecular weight substances of a protein nature, but in some cases complex carbohydrates (polysaccharides) may act as antigens.

Antigens are substances that stirnulate the formation of antibodies within an animal and react observably with that antibody. They generally possess a high molecular weight of 10,000 or more.

While the list below is not meant to be all inclusive (a detailed description is set forth in P. L. Carpenter, Immunology and Serology, 2nd Edition, 1968), typical antigens may be classified as follows: (1) protein antigens, such as ceruloplasmin and serum albumin; (2) bacterial antigens, such as teickoic acids, flagellar antigens, capsular polysaccharides, and extra-cellular bacterial products and toxins; (3) blood group antigens, such as glycoproteins.

and glycolipids; (4) viruses, such as animal, plant, and bacterial viruses; (5) conjugated and synthetic antigens, such as proteinhapten conjugates, and synthetic polypeptides; and (6) nucleic acids, such as ribonucleic acid and deoxyribonucleic acid.

Immunity may be natural or acquired, and in the latter case may be acquired naturally or artificially.

Artificial immunity, as is well known, can be either passive, i.e., by injection of an antiserum (prophylactic, therapeutic), or active, as by vaccination with, for example, live or dead organism.

immunization procedures are important in the prevention of various diseases including viral diseases. There is also considerable evidence that viruses do cause various kinds of tumors and cancerous growths, particularly in lower animals such as rabbits, mice, chickens, and hamsters. Various investigators, including the present Applicant, have also been active in their attempt to discover agents that might be effective in cancer immunotherapy. See Lekhite,V.V., "Clinical Cancer Immunotherapy: Experience in Breast and Lung Cancer", in Immunocancerology in Solid Tumors, (Martin, M.

and Dionne, L., eds.) pp. 135-141. (Stratton, 1976).

"Rejection of Tumor Metastases in Fisher 344 Rats Following Administration of Killed Corynebacterium parvum", Cancer Immunology and Immunotherapy, (1977), Vol. 2, pp. 173-178. V.V. Likhite.

In response to an injection of antigens, the body of an animal produces specific antibodies which react with and neutralize the antigens. Antibodies are classified as proteins with the solubility of globulins and the electrophoretic mobility of gamma globulin.

The molecular weight of gamma globulins, or as they are also called "immune globulins", varies from 160,000 to 1,000,000 and these immune globulins (Ig) are subgrouped into five classes, according to molecular weight, i.e., lg G, Ig A, Ig D, lg E, and lg M.

The lg G class, or group, is the most prevalent in serum and is characterized by a molecular weight of 160,000. The lg M class is the least prevalent and is characterized by a molecular weight of 1,000,000.

Sometimes it is necessary that a large supply of antibodies appear in a person's blood immediately in order to combat an overwhelming infection already present in the body. Accordingly, the patient must receive ready-made antibodies, and various means are known for the manufacture and recovery of antigens and antibodies, these being merely exemplified by United States Patents Nos. 3,652,761 and 3,843,444.

In U.S. 3,652,761, there is disclosed an immunochemical composite comprising an antigen or antibody chemically coupled to an inorganic carrier. As the antigen or antibody becomes insolubilized, when so coupled, this, according to the patentee, provides a better means of recovery of a more pure antigen or antibody.

U.S. 3,843,444, which issued to Applicant on October 1974, discloses a means for concentration, separation, and recovery of macromolecular substances having mutual attraction for one another, particularly biological substances such as antibodies and antigens. The invention makes use of the discovery that antigens and antibodies, which are specific for one another, can be preferentially attracted to opposite surfaces of thin semipermeable members.

These various known procedures for manufacture and recovery of antigens and antibodies, while satisfactory to a degree, are attendant with certain disadvantages. One major disadvantage with some prior known systems results from the fact that antigens and antibodies are mutually attracted to one another. This attraction interferes with purification and recovery of antibodies. The recovered product, in many instances, has been markedly reduced to a fraction, e.g. 5-20%, ofthe original physiological activity. When an animal receives repeated injections of a given antigen, the induced specific antibody response in the host animal against the injected antigen represents a relatively small amount, usually less than 1%, of the serum globulin pool.The quantities response, moreove(, has not been improved beyond the hos. capabilities.

There is a need, not only for a method of produc ing larger quantities of antibodies within a biological system, but also improved methods of recovery of antibodies without loss of appreciable activity.

The above disadvantages are overcome by the present invention which comprises in its basic aspects certain antigens and antigen conjugates useful in the production of higher titers of specific antibodies than obtainable heretofor. The antigens of the invention are also found useful in diagnostic medicine, analytical biochemistry, and immunotherapy.

The invention in its more specific aspects is an antigen which comprises certain killed microorganisms or a plant extract which when chemically coupled to another antigen acts as an immunostimulant adjuvant, inducing high titer antibody response specific to the antigen conjugate. This secondary antigen can be a physiological substance such as a virus ortumorcells in which case the antigen conjugate functions as a chemotherapeutic product.

Quite advantageously, although all the antigens of the present invention can be used in the manufacture of high titers of specific antibodies, a different response can be obtained in the host biological system, depending on the particular antigen used.

When the primary antigen is a new strain of Listeria monocytogenes the invention provides, most importantly, a means by which specific high molecular weight antibodies, i.e. lg M, specific to the antigen can be produced, when the antigen is injected into an animal. These antibodies are recoverable by rather simple procedures that allow for easy separation due to the inherent characteristics of these high molecular weight antibodies, and most importantly without impairing their physiological properties to any great degree, if at all.

The specific lg M antibodies ofthe invention, lg M antibodies being pentamers of lg G antibodies, can be separated, moreover, into lg G antibodies by means of physiologically mild reducing agents without appreciable loss oftheirspecific activity.

The specific lg M antibodies ofthe invention can be, moreover, quite advantageously, tagged or labeled with a vital dye (stain) for use in diagnostic applications. This permits use of a conventional light microscopy instead of flu roscent microscopy.

Ig M antibodies according to the invention can, moreover, be coupled with chemotherapeutic agents such as antibodies and anticancer drugs for the treatment of the specific disease-causing agents (towards which the antibody has already been formed). Bacteria, viruses, tumor cells and other infectious agents can be combined with the immunopotentiating agent and such combination used a therapuetic substance.

The new strain of Corynebacteriam parvum and Corynebacteriam paragranulosum according to the invention not only induces high titers of lg G, but also advantageously affect the macrophage systems.

The third microorganism antigen ofthe invention, a new strain of Bordetella pertussis, as well as the plant extract (SpeciesRhus) induces high titers of lg E.

Subcultures ofthe newly discovered bacteria strains Bordetella pertussis akka, Listeria monocytogenes akka, Corynebacteriam parvum akka, and Cornyebacteriam paragranulosum, used in the practice of the invention have been deposited with, and can be obtained upon request from the permanent coliection of, the Northern Regional Research Laboratories (NRRL), Agricultural Research Services, U.S. Department of Agriculture, Peoria, Illinois, U.S.A. Their accession numbers in this repository are NRRL B-11,232; NRRL B-11,233; NRRL B-1 1,234; NRRL B-11,235; respectively. The strains were all deposited at NRRL on December 7, 1977.

These mutant strains have characteristics similar to those of other strains of their Genus and grow in th same media, but they have immunotherapeutic value.

In accordance with one aspect of the invention, certain antigens have been discovered which, when injected into an animal, result in a response to evoke relatively high titers of antibody.

Those antigens which have been found to accomplish this desirable antibody response, are novel killed strains of three bacteria, Listeria monocytogenes akka, Bordetella pertussis akke, and Corynebac teriamparvum akka and Corynebacteriam paragranulosum, and a plant extract from the plant species Thus.

Other antigens, i.e. secondary antigens, can be sensitized to evoke the same high antibody response by chemically coupling them to the abovementioned primary antigens. In this regard the primary antigens function as an immunopotentiating agent, or as such might also be called, an immunostimulant adjuvant.

The secondary antigens can be any of those commonly known as antigens, however, the secondary antigen of the invention can, quite advantageously, be a physiological substance such viruses, hormones, bacteria, and tumor cells. This results from the fact that a common characteristic ofthe primary antigens is their ability to function as immunotherapeutic agents. Thus, when a secondary antigen such as a live tumor cell is coupled to a primary antigen such as the novel strain ofBordetella pertussis akka, a chemotherapeutic product results which, when injected into an animal having that tumor induces a response that results in rejection of the tumor. Growing tumors can therefore be treated by injecting a human or animal having the tumor repeatedly with a conjugate of a like tumor cell coupled to an immunostimulant adjuvant having the ability to activate the recticuloendothelial and lymphoproliferative systems towards the sensitising antigens. Similarly when an antigen conjugate couples a virus with an immunopotentiating agent in accordance with the invention, the injection of such a conjugate into an animal affects treatment of the viral infection by stimulation of host defenses against viral infections.

Coupling of the secondary antigen to the primary antigen can be accomplished by means of various chemical agents providing two reactive sites such as, for example, bisdiazobenzidine, glutaraldehyde, m-xylenediisocyanate, di-iodoacetate, and a diisocyanate such as toluene-2, 4 diisocyanate. The latter coupling agent is more preferred for a number of reasons. First of all the NCO groups readily react with free NH2 groups. However, and this is a most desirable feature in using toluene-2, 4 diisocyanate, only the NCO group at the 4th carbon remains active at 4"C. Thus, its use as a coupling agent permits coupling of the killed bacteria strain or plant extract first at the 4th carbon position, followed by coupling of a second antigen at the second carbon position.If desired, however, the so-called "secondary antigen" can be coupled to the 4th carbon position first, followed by coupling ofthe immunostimulant adjuvant, or primary antigen, to the 2nd carbon position.

Although a common characteristic ofthe microorganism antigens ofthe present invention is their ability to act as therapeutical agents, each of the primary antigens differ somewhat in the antibody response induced. Nevertheless, a high titer is common, sometimes reaching quantities as high as 6 gm percent in the host serum, an unexpectedly high result.

The invention provides in the use ofthe novel strain of Listeria monocytogenes not only a means of producing large quantities of high molecular weight antibodies, lg M, but also a means for the recovery of these antibodies as pure and active antigen-specific antibodies. This results from the fact that such antibodies are characterized by insolubility in cold temperature, e.g. 4"C, making for ease in separation and recovery of a purified product, from the serum, as hereinafter more fully disclosed. The Ig M goes back into solution when suspended in physiological buffer solution with heating to 31 C.

As the Ig M antibodies maintain their antigen specific immunochemical characteristics, they are more desirable for use in diagnostic and therapeutic immunology. The purified antibody, i.e., the antibody recovered, reacts only with the Listeria monocytogenes organism or the coupled antigen and organism, according to the invention.

The Ig M antibodies can, if desired, be separated into five sunbunits of lg G antibodies, which also exhibit the specificities as the Ig M antibodies, by exposure to various mild physiological reducing agents. Examples of these are mercaptoethanol and cysteine. Thus, it is possible to produce higher titers than heretofore of Ig G antibodies, and of a desirable purity, which can be used in various immunochemical applications including radioimmunoassay.

Although recovery of Ig M antibodies can be based on their insolubility at cold temperatures, this method of recovery need not be the only one employed. Sheep red blood cells can be used, according to conventional techniques. Other methods of recovery of Ig M include column chromatography using sephadex or sepha rose 6200, the Ig M being represented in the first peak of protein eluted. These alternative methods are less preferred, however, as they do result in some, though not appreciable, loss of specific activity.

It has also been discovered, quite unexpectedly, that a protein extract from the culture medium in which the microorganisms of the invention are grown induces the same responses as the microorganism.

After the microorganism strain is recovered, the medium is saturated with (NH4)2SO4, and allowed to precipitate out overnight. It is then dialized against standard buffer and used as primary antigen.

The invention may be more fully understood by reference to the following examples which illustrate certain embodiments ofthe invention.

ISOLATION OF MICROORGANISMS EXAMPLE 1 Using conventional sterile technique a novel strain ofListeria monocytogenes was isolated from a patient having lung cancer but who died from listeriosis. The isolate was grown in 500 ml standard culture medium (Todd-Hewitt), according to known procedures, over a period of about 24 hours. This strain is NRRL B-i 1,233.

The culture medium was then heated at 600C for a sufficient time, e.g. about one hour, to kill the bacteria. This was determined by a lack of growth when the material was placed on blood agar plates.

The broth was next centrifuged according to conventional techniques at 3000 g for 20 minutes to harvest the killed bacteria cells, the supernate being saved for extraction of the associated active protein.

The recovered killed bacteria cells were then suspended in 50 mi standard Phosphate Buffered Saline (PBS, pH 7.4) and this suspension then centrifuged, as previously described, and the bacteria cells again harvested. The procedure was then twice repeated to make certain the cells were clean.

EXAMPLE2 Using the procedure as described in Example 1, a novel strain of the bacteria Bordetella pertussis was isolated and recovered from a child patient having hooping cough. This strain is NRRL B-11,232.

EXAMPLE 3 The procedure of Example 1 was used to recover the novel strain, Corynebacteriam parvum akka, from a patient having a malignant colonic cancer (w/o metastases) and a huge spleen, but who died of a heart attack. The medium used, however, was a standard anerobic/heart brain infusion broth. This strain is NRRL B-i 1,234. Similarly, the microorganism Corynebacteriam paragranulosum was isolated This strain is NRRL B-11,235.

PRODUCTION OF PLANT EX TRACT EXAMPLE 4 Cut leaves from the plant Thus were homogenized with 95% ethanol, after which the supernate was centrifuged off. The residue was allowed to dry, after which it was ready for use.

PRODUCTION OF ANTIBODY USING PRIMARY ANTIGENS EXAMPLE 5 The bacteria strains of Examples 1-3 and the plant extract of Example 4 were each suspended in standard PBS, p.7.4, according to usual technique and separately injected into experimental animals over a period of several weeks.

When the animals were bled and antibody titer determined, was found to be unexpectedly high.

The antibodies recovered were antigen-specific, depending upon the particular antigen utilized,lg M was produced using he s'.:'-,Ar Listena mono- cytogenes akka 9L8-1. B-1 1,233; the strain Cerynha teriam parve m akka NRRL B-11,234, as did Corynebacteriam paragranulosum NPP..L 8-11,235, resulted in lg G; and the strains ofB. pertussis aM'.a NRRL B-11,232 and the plant extract induced Ig E antibodies.

PRODUCTION OFA NT'GE(v CONJUGA TE E,YAMPLE 6 The harvested killed bacteria cells of Example 1 (Listeria monocytogenes NRRL B-11,233) were resuspended in 6 ml standard PBS, pH 8.6, in a 25 ml Ehrlenmeyer flask, and the contents placed at 4"C fcr 30 minutes. Toluene-2, 4 diisocyanate (TDIC), which meanwhile had been cooled to 4 C, was then added dropwise to the flask, with constant stirring, over a period of 1 hour, 100 mg total being added. This solution was then allowed to sit for 30 minutes in order that the TDIC was conjugated with the killed bacteria.

The suspension was then centrifuged (3000 g for 20 minutes) and the supernatant material discarded.

The recovered antigen conjugate (bacteria-TDlC) was then resuspended in 8 ml std. PBS, pH 7.4, and again washed by centrifugation, as before.

The washed antigen conjugate was then resuspended in 6 ml std. PBS, pH 7.4, and 500 mg bovine serum albumin (50% solution in std. PBS, p 7.4, dialyzed previously according to conventional techniques) was then added to the suspension. This mixture was then placed at 37"C and stirred (magnetic stirrer) for 1 hour, after which it was allowed to sit for 30 minutes. The suspension was then washed by centrifugation, as before described. It was then determined according to usual techniques that 2 mg albumin were conjugated to 109 bacterial cells.

These solutions were then stored at-70 C until ready for use.

EXAMPLE 7 In a manner as disclosed in Example 6, the strain of B. pertussis NRRL B-i 1,232 disclosed in Example 2 is coupled to toluene-2, 4 diisocyanate, except that rather than reducing the temperature so as to couple the bacteria to the carbon 4-NCO group, it was coupled to the carbon 2-NCO group, at 37"C. Live tumor cells (T 1699-mammary adenocarcinoma, The Jackson Laboratory, Bal Harbour, Maine, U.S.A.) were first coupled at the 4th carbon site.

PRODUCTION OFANTIGEJV-AAITIBODY COMPLEX '(AMPLE8 0.25 ml of the solution of Example 6 were injected intravenously into each of several experimental rabbits at weekly intervals for five weeks, during which time the rabbits were producing antibodies in response to the presented antigen conjugate.

A week following the last injection, the rabbits were bled (from 50 ml to 120 ml of blood was obtained from each rabbit). The antibody titer was determined according to conventional procedures and was found to be unexpectedly high. Measure ments were discontinued after 1/6,000,000 dilution of the serum.

At this point, the blood can either be allowed to heparinize or clot (at 37 C) for further processing. RECOVERY OFANTIBODY EXAMPLE 9 The blood samples from the rabbits of Example 8 Alere allowed to clot and the serum then placed at 4 for 24 hours. At this temperature the gamma M globulins (due to their inherent nature) precipitate and can then be recovered. This was accomplished by centrifugation (1000 g x 10 min.) at4"C, after which the precipitated gamma M globulins were washed rwice by centrifugation, using cold std. PBS, PH 7.4.

The recovered precipitate was then resuspended n std. PBS, pH 7.4, depending on the original volume cf blood, and these suspensions warmed to room temperature, at which time the precipitate became solubie.

In this manner from 2 to 7 grams of gamma M globulins were separated. 6 mg of the globulins recovered reflected about 1/250,000 titer to albumin, indicating that all antibody recovered was albumin specific.

SEPARATION GAMMA M GLOBULINS INTO SUB UNITS EXAMPLE 10 An equal volume of the lg M from Example 9 was added to 0.06 M cysteine in std. PBS, pH 7.4 and this mixture was incubated at 37"C for two hours. This caused the gamma M globulins to separate into gamma G globulin subunits. These are found to react in the same manner with the albumin, without loss of specific activity.

USE OFANTIGEN CONJUGA TEAS CHEMO THERAPEUTIC PRODUCT EXAMPLE IT This example is directed to the immunotherapeutic treatment of growing tumors by the injection of mice with the Bordetella pertussis NRRL B-11,232 (new strain) - lCTD -tumor cell antigen conjugate of Example 7, the data having been published in ARCS Medical Science, 4,565 (1976), this article being authored by Applicant and incorporated completely herein by reference.

Approximately 106 living syngeneic T1699 mammary adenocarcinoma cells (The Jackson Laboratory) were transplanted subcutaneously in the lateral posterial flank of 100 previously unsensitized DBA/2 mice (females, age 5 weeks, The Jackson Laboratory). Seven days later (mean tumor diameter 0.2 cm) the mice were separated into 5 groups of 20 animals each.

The mice in each group were then each given weekly ( x 4) intraperitoneal injections of one ofthe following: (1) Standard Phosphate Buffered Saline, pH 7.4; (2) living 106 Ti 699 cells coupled with ICTD at carbon position 4; (3) new strain killed Bordetella pertussis NRRL B-11,232 (5 x 107 organisms) according to invention; (4) separately new strain killed Bor dete/la pertussis NRRL B-11,232 (5 x 107) and living 106 T1699 tumor cells; and (5) live 106 T1699 tumor cells coupled specifically with 5 x 107 new strain killed Bordetella pertussis NRRL B-l 1,232 using ICTD (ICTD, as disclosed in Example 7 allows for first coupling the tumor cells only at carbon position 4 at 40C, and then B. pertussis at carbon position 2 which is active at 37"C; however, reverse could be done also, if desired). The mice were inspected at twice weekly intervals and two tumor diameters were measured on each mouse until death.

Only the mice of group 5, i.e., the mice treated with the chemotherapeutic product comprising tumor cell - lCTD -B. pertussis NRRL B-i 1,232 conjugate, according to the invention, survived. These animals exhibited expected rates of tumor growth for 8 days, even after therapy was initiated; however, this was followed by regression of tumor size and disappearance ofthetumor in 20/20 mice. These particular mice have survived tumor free for more than 18 months.

The mice in the remaining four groups all died with growing tumors and metastases (seen on autopsy). Of these, the mice in groups 3 and 4, i.e., those treated with killed B. pertussis NRRL B-11,232 (new strain) alone, or together with separate injections of T1699 tumor cells, surprisingly exhibited accelerated rates of tumor growth.

These studies were repeated and similar results were obtained.

EXAMPLE 12 The immunotherapy of Example 11 was repeated except that SAD2 sarcoma and CAD2 mammary adenocarcinoma syngeneicto DUBAI2 mice and the R3230 and 13762 mammary adenocarcinomas syngeneic to Fischer 344 rats were evaluated, rather than the Tri 699 tumor cei Is.

Similar results were obtained and long term tumor free survivals.

Claims (23)

1. An antigen suitable for use in the production of antibody specific thereto, said antigen comprising killed bacteria selected from the strains Listeria monocyteogenes NRRL B-i 1,233, Bordetella pertussis NRRL B-l 1,232, Corynebacteriam parvum NRRL B-11,234 and Corynebacteriam paragranulosum NRRL B-i 1,235, a protein extract obtained from a culture medium in which one of said strains has grown, or a plant extract of the plant species Rhus.

2. An antibody prepared by injecting into a host human or animal an antigen as claimed in claim 1, allowing sufficient time for an antibody response specific to said antigen to build up, and recovering from said host said antibody.

3. An antibody according to claim 2 which is lgM, said antigen being killed Listeria monocyteogenes NRRL B-11,233.

4. An antibody according to claim 2 which is IgE, said antigen being killed Bordetella pertussis NRRL B-11,232.

5. An antibody according to claim 2 which is lgG, said antigen being killed Corynebacteriam parvum NRRL B-11,234.

6. An antibody according to claim 2 which is lgG, said antigen being killed Corynebacteriam paragranulosum NRRL B-11,235.

7. An antibody according to claim 2 which is IgE, said antigen being a plant extract of the plant species Thus.

8. An antibody according to claim 3 wherein the IgM is recovered from serum obtained from the host by: (1) reducing the temperature of the serum to 40C whereby the IgM antibodies precipitate; and (2) centrifuging the supernatant from the precipitate.

9. An antibody according to any one of claims 2 to 8 wherein said host human or animal is healthy.

10. An antigen conjugate suitable for use in the production of antibody specific thereto, said conjugate comprising an immuno-stimulant adjuvant consisting of a primary antigen as claimed in claim 1 coupled to a secondary antigen.

11. A conjugate according to claim 10 wherein said primary antigen and said secondary antigen have been coupled together by means of a coupling agent having two reactive sites, either of which is capable of reaction with either of said antigens.

12. A conjugate according to claim 11 wherein the coupling agent is a diisocyanate.

13. A conjugate according to claim 12 wherein the diisocyanate is toluene-2, 4 diisocyanate.

14. A conjugate according to claim 13 wherein the primary antigen is killed Listeria monocytogenes NRRL B-11,233 which is coupled to said coupling agent at only one of the reactive sites.

15. A conjugate according to claim 14 wherein the primary antigen is coupled to the fourth carbon position of said coupling agent.

16. A conjugate according to any one of claims 10 to 15 wherein the secondary antigen comprises a physiological substance.

17. A conjugate according to claim 16 wherein the physiological substance is a virus, hormone, bacterium or tumor cell.

18. A conjugate according to any one of claims iOto 13 wherein said primary antigen comprises killed Bordetella pertussis NRRL B-i 1,232 and the secondary antigen comprises a living tumor cell.

19. Aconjugate according to claim 10 substantially as hereinbefore described in Example 6 or 7.

20. A process for the preparation of an antigen conjugate suitable for use in the production of antibody specific thereto, which process comprises (a) coupling an immunostimulant adjuvant consisting of an antigen as claimed in claim 1 to a chemical coupling agent having two reactive sites, said adjuvant being coupled to only one of said two sites; and (b) coupling another antigen to the other of said reactive sites.

21. A process according to claim 20 wherein the coupling agent is toluene-2, 4 diisocyanate.

22. A process according to claim 20 substantially as hereinbefore described in Example 6 or 7.

23. An injectable formulation comprising, as active ingredient, an antigen as claimed in claim 1, an antibody as claimed in any one of claims 2 to 9, an antigen conjugate as claimed in any one of claims 10 to 19 or an antigen conjugate which has been prepared by a process as claimed in any one of claims 20 to 22, together with a pharmaceutically acceptable diluent.